专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07566720B2 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a] pyrimidin-5(1H)one derivatives 失效
标题翻译： 2-吡啶基-6,7,8,9-四氢嘧啶并[1,2-a]嘧啶-4-酮和7-吡啶基-2,3-二氢咪唑并[1,2-a]嘧啶-5（1H）
公开(公告)号：US07566720B2
公开(公告)日：2009-07-28
申请号：US11841285
申请日：2007-08-20
申请人： Antonio Almario Garcia , Thierry Gallet , Adrien Tak Li , Alistair Lochead , Severine Marguerie , Alain Nedelec , Mourad Saady , Philippe Yaiche
发明人： Antonio Almario Garcia , Thierry Gallet , Adrien Tak Li , Alistair Lochead , Severine Marguerie , Alain Nedelec , Mourad Saady , Philippe Yaiche
IPC分类号： A61P25/00 , A61P25/28 , A61P3/04 , C07D471/04 , C07D487/04 , A61K31/519
CPC分类号： C07D487/04 , A61K31/519
摘要： The invention relates to therapeutic uses of a pyrimidone derivative represented by formula (I) or a salt thereof: Wherein X, Y, R1, R2, m and n are as defined herein. Specifically, a medicament comprising the said derivative or a salt thereof as an active ingredient is used for preventive and/or therapeutic treatment of a neurodegenerative diseases caused by abnormal activity of GSK3β such as Alzheimer's disease.
摘要翻译：本发明涉及由式（I）表示的嘧啶酮衍生物或其盐的治疗用途：其中X，Y，R 1，R 2，m和n如本文所定义。具体地说，包含所述衍生物或其盐作为活性成分的药物用于预防和/或治疗由诸如阿尔茨海默病的GSK3β的异常活性引起的神经变性疾病。

2. 发明申请

US20060014762A1 2-Pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-A]pyrimidin-4-one and 7-pyridinyl-2,3-dihydoimidazo[1,2-A]pyrimidin-5(1H)one derivatives 审中-公开
公开(公告)号：US20060014762A1
公开(公告)日：2006-01-19
申请号：US11227007
申请日：2005-09-15
申请人： Antonio Almario Garcia , Thierry Gallet , Adrien Ll , Alistair Lochead , Severine Marguerie , Alain Nedelec , Mourad Saady , Philippe Yaiche
发明人： Antonio Almario Garcia , Thierry Gallet , Adrien Ll , Alistair Lochead , Severine Marguerie , Alain Nedelec , Mourad Saady , Philippe Yaiche
IPC分类号： A61K31/519 , C07D487/04
CPC分类号： C07D487/04 , A61K31/519
摘要： The invention relates to a pyrimidone derivative represented by formula (I) or a salt thereof: wherein: X represents hydrogen atoms, a sulphur atom, an oxygen atom or a C1-2 alkyl group and a hydrogen atom; Y represents a bond, an ethenylene group, an ethynylene group, a 1,2-cyclopropylene, an oxygen atom, a sulphur atom, a sulfonyl group, a sulfoxyde group, a carbonyl group, a nitrogen atom being optionally substituted; or a methylene group optionally substituted; R1 represents a 2, 3 or 4-pyridyl group optionally substituted by a C3-6 cycloalkyl group a C1-4 alkyl group, a C1-4 alkoxy group, a benzyl group or a halogen atom; when Y represents a bond, a methylene group optionally substituted or a carbonyl group then R2 represents a C1-6 alkyl group, a C3-6 cycloalkyl group, a C1-4 alkylthio group, a C1-4 alkoxy group, a C1-2 perhalogenated alkyl group, a C1-3 halogenated alkyl group, a 5,6,7,8-tetrahydronaphthyl ring, a naphthyl ring, a phenylthio group, a benzyl group, a phenyl ring, a pyridyl ring, an indole ring, a pyrrole ring, a thiophene ring, a furan ring or an imidazole ring; when Y represents an ethenylene group, an ethynylene group, an oxygen atom, a sulphur atom, a sulfonyl group, a sulfoxyde group or a nitrogen atom being optionally substituted then R2 represents a C1-6 alkyl group, a C3-6 cycloalkyl group, a C1-2 perhalogenated alkyl group, a C1-3 halogenated alkyl group, a naphthyl ring, a 5,6,7,8-tetrahydronaphthyl ring, a benzyl group, a phenyl ring, a pyridyl ring, an indole ring, a pyrrole ring, a thiophene ring, a furan ring or an imidazole ring. And a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative diseases caused by abnormal activity of GSK3β such as Alzheimer's disease.

3. 发明授权

US06974819B2 2-pyridinyl-6,7,8,9-tetrahydropyrimido{1,2-a}pyrimidin-4-one and 7-pyridinyl-2,3-dihydoimidazo{1,2-a}pyrimidin-5(1H)one derivatives 失效
标题翻译： 2-吡啶基-6,7,8,9-四氢嘧啶并[1,2-a]嘧啶-4-酮和7-吡啶基-2,3-二氢咪唑并[1,2-a]嘧啶-5（1H）
公开(公告)号：US06974819B2
公开(公告)日：2005-12-13
申请号：US10362850
申请日：2001-08-31
申请人： Antonio Almario Garcia , Thierry Gallet , Adrien Tak Li , Alistair Lochead , Séverine Marguerie , Alain Nedelec , Mourad Saady , Philippe Yaiche
发明人： Antonio Almario Garcia , Thierry Gallet , Adrien Tak Li , Alistair Lochead , Séverine Marguerie , Alain Nedelec , Mourad Saady , Philippe Yaiche
IPC分类号： A61K31/519 , A61P3/04 , A61P3/10 , A61P9/00 , A61P9/10 , A61P17/14 , A61P23/02 , A61P25/00 , A61P25/02 , A61P25/16 , A61P25/24 , A61P25/28 , A61P27/06 , A61P35/00 , A61P35/02 , C07D487/04
CPC分类号： C07D487/04 , A61K31/519
摘要： Imidazo[1,2-α]pyrimidinones and pyrimido[1,2-α]pyrimidinones useful for preventive and/or therapeutic treatment of neurodegenerative diseases, such as Alzheimer's disease, caused by abnormal GSK3β activity.
摘要翻译：咪唑并[1,2-α]嘧啶酮和嘧啶并[1,2-α]嘧啶酮，用于预防和/或治疗由异常GSK3β活性引起的神经变性疾病，如阿尔茨海默病。

4. 发明授权

US07462621B2 Use of substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a] pyrimidin-5(1H)one derivatives as therapeutic agents 失效
标题翻译：取代的2-吡啶基-6,7,8,9-四氢嘧啶并[1,2-a]嘧啶-4-酮和7-吡啶基-2,3-二氢咪唑并[1,2-a]嘧啶-5（1H ）一种衍生物作为治疗剂
公开(公告)号：US07462621B2
公开(公告)日：2008-12-09
申请号：US11696982
申请日：2007-04-05
申请人： Thierry Gallet , Patrick Lardenois , Alistair Lochead , Severine Marguerie , Alain Nedelec , Mourad Saady , Franck Slowinski , Philippe Yaiche
发明人： Thierry Gallet , Patrick Lardenois , Alistair Lochead , Severine Marguerie , Alain Nedelec , Mourad Saady , Franck Slowinski , Philippe Yaiche
IPC分类号： C07D487/04 , A61K31/519 , A61P25/28 , A61K31/55
CPC分类号： A01N43/90 , C07D213/50 , C07D213/60 , C07D487/04
摘要： The invention relates to an use of pyrimidone derivative represented by formula (I) or a salt thereof: wherein m, n, p, X, Y, R1, R2, R3, R4 and R5 are as defined herein for treating a variety of disease states. More specifically, the invention relates to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β or GSK3β and cdk5/p25, such as Alzheimer's disease.
摘要翻译：本发明涉及由式（I）表示的嘧啶酮衍生物或其盐的用途：其中m，n，p，X，Y，R 1，R 2，R 3，R 4和R 5如本文所定义，用于治疗各种疾病状态。更具体地，本发明涉及包含所述衍生物或其盐作为活性成分的药物，其用于预防和/或治疗由GSK3β或GSK3β和cdk5 / p25的异常活性引起的神经变性疾病的预防和/或治疗，例如阿尔茨海默氏病。

5. 发明授权

US07781440B2 Use of substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a] pyrimidin-5(1H)one derivatives 失效
标题翻译：取代的2-嘧啶基-6,7,8,9-四氢嘧啶并[1,2-a]嘧啶-4-酮和7-嘧啶基-2,3-二氢咪唑并[1,2-a]嘧啶-5（1H ）一个衍生物
公开(公告)号：US07781440B2
公开(公告)日：2010-08-24
申请号：US12120496
申请日：2008-05-14
申请人： Thierry Gallet , Patrick Lardenois , Alistair Lochead , Severine Marguerie , Alain Nedelec , Mourad Saady , Franck Slowinski , Philippe Yaiche
发明人： Thierry Gallet , Patrick Lardenois , Alistair Lochead , Severine Marguerie , Alain Nedelec , Mourad Saady , Franck Slowinski , Philippe Yaiche
IPC分类号： A61K31/519 , A61P25/00 , A61P25/28
CPC分类号： A61K31/519 , A61K31/551 , C07D487/04
摘要： The invention relates to use of a pyrimidone derivative represented by formula (I) or a salt thereof as therapeutic agents: Wherein m, n, p, X, Y, R1, R2, R3, R4 R5, are as defined herein. The invention specifically relates to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β or GSK3β and cdk5/p25, such as Alzheimer disease.
摘要翻译：本发明涉及由式（I）表示的嘧啶酮衍生物或其盐作为治疗剂的用途：其中m，n，p，X，Y，R 1，R 2，R 3，R 4 R5如本文所定义。本发明具体涉及包含所述衍生物或其盐作为活性成分的药物，其用于预防和/或治疗由GSK3和bgr的异常活性引起的神经变性疾病; 或GSK3＆bgr; 和cdk5 / p25，如阿尔茨海默病。

6. 发明申请

US20080269257A1 Use of Substituted 2-Pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-A] Pyrimidin-4-one and 7-Pyrimidinyl-2,3-dihydroimidazo[1,2-A] Pyrimidin-5(1H)one Derivatives 失效
标题翻译：使用取代的2-嘧啶基-6,7,8,9-四氢嘧啶并[1,2-A]嘧啶-4-酮和7-嘧啶基-2,3-二氢咪唑并[1,2-A]嘧啶-5（1H ）一个衍生品
公开(公告)号：US20080269257A1
公开(公告)日：2008-10-30
申请号：US12120496
申请日：2008-05-14
申请人： Thierry Gallet , Patrick Lardenois , Alistair Lochead , Severine Marguerie , Alain Nedelec , Mourad Saady , Franck Slowinski , Philippe Yaiche
发明人： Thierry Gallet , Patrick Lardenois , Alistair Lochead , Severine Marguerie , Alain Nedelec , Mourad Saady , Franck Slowinski , Philippe Yaiche
IPC分类号： A61K31/519 , C07D487/02 , A61P25/28 , A61P25/00
CPC分类号： A61K31/519 , A61K31/551 , C07D487/04
摘要： The invention relates to use of a pyrimidone derivative represented by formula (I) or a salt thereof as therapeutic agents: Wherein m, n, p, X, Y, R1, R2, R3, R4 R5, are as defined herein. The invention specifically relates to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β or GSK3β and cdk5/p25, such as Alzheimer disease.
摘要翻译：本发明涉及由式（I）表示的嘧啶酮衍生物或其盐作为治疗剂的用途：其中m，n，p，X，Y，R 1，R 2，R 3，R 4 R5如本文所定义。本发明具体涉及包含所述衍生物或其盐作为活性成分的药物，其用于预防和/或治疗由GSK3β或GSK3β和cdk5 / p25例如阿尔茨海默病异常活动引起的神经变性疾病。

7. 发明申请

US20050049261A1 Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido{1,2-a}pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo{1,2-a}pyrimidin-5(1h)one derivatives 失效
标题翻译：取代的2-吡啶基-6,7,8,9-四氢嘧啶并[1,2-a]嘧啶-4-酮和7-吡啶基-2,3-二氢咪唑并[1,2-a]嘧啶-5（1h）衍生品
公开(公告)号：US20050049261A1
公开(公告)日：2005-03-03
申请号：US10490135
申请日：2002-09-19
申请人： Thierry Gallet , Patrick Lardenois , Alistair Lochead , Severine Marguerie , Alain Nedelec , Mourad Saady , Franck Slowinski , Philippe Yaiche
发明人： Thierry Gallet , Patrick Lardenois , Alistair Lochead , Severine Marguerie , Alain Nedelec , Mourad Saady , Franck Slowinski , Philippe Yaiche
IPC分类号： A61K31/519 , A61P3/04 , A61P3/10 , A61P9/10 , A61P17/14 , A61P25/00 , A61P25/02 , A61P25/08 , A61P25/16 , A61P25/18 , A61P25/24 , A61P25/28 , A61P27/02 , A61P27/06 , A61P35/00 , A61P43/00 , C07D213/50 , C07D213/60 , C07D487/04
CPC分类号： A01N43/90 , C07D213/50 , C07D213/60 , C07D487/04
摘要： The invention relates to a pyrimidone derivative represented by formula (I) or a salt thereof wherein X represents two hydrogen atoms, a sulfur atom, an oxygen atom or a C1-2 alkyl group and a hydrogen atom; Y represents a bond, an ethenylene group, an ethynylene group an oxygen atom, a sulfur atom, a sulfonyl group, a sulfoxide group, a carbonyl group, a hydroxyiminomethylene group, a dioxolan group, a nitrogen atom being optionally substituted; or a methylene group optionally substituted; or a methylene group optionally substituted; R1 represents a 2, 3 or 4-pyridine ring optionally substituted; R2 may represent a C1-6 alkyl group optionally; a C3-6 cycloalkyl group, a C1-4 alkythio group, a C1-4 alkoxy group, a C1-2 perhalogenated alkyl group, a C1-3 halogenated alkyl group, a phenylthio group, a benzyl group, a benzene ring, an indan ring, a 5,6,7,8-tetrahydronaphthalene ring, a naphthalene ring, a pyridine ring, a pyrrole ring, a thiophene ring, a furan ring or an imidazole ring; R3 and R4 represent, each independently, a hydrogen atom, a C1-6 alkyl group, a hydroxy group, a C1-4 alkoxy group or a halogen atom; R5 represents a hydrogen atom, a C1-6 alkyl group or a halogen atom; with the proviso that when R3 and R4 represent each a hydrogen atom then R5 is not a hydrogen atom. The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β or GSK3β, and cdk5/p25, such as Alzheimer disease.
摘要翻译：本发明涉及由式（I）表示的嘧啶酮衍生物或其盐，其中X表示两个氢原子，硫原子，氧原子或C 1-2烷基和氢原子; Y表示键，亚乙烯基，亚乙炔基，氧原子，硫原子，磺酰基，亚砜基，羰基，羟基亚氨基亚甲基，二氧戊环基，任选取代的氮原子; 或任选取代的亚甲基; 或任选取代的亚甲基; R1表示任选取代的2,3或4-吡啶环; R 2可以任选地表示C 1-6烷基; C 3-6环烷基，C 1-4链炔基，C 1-4烷氧基，C1-2全卤代烷基，C 1-3卤代烷基，苯硫基，苄基，苯环，茚满环，5,6,7,8-四氢萘环，萘环，吡啶环，吡咯环，噻吩环，呋喃环或咪唑环; R 3和R 4各自独立地表示氢原子，C 1-6烷基，羟基，C 1-4烷氧基或卤素原子; R5表示氢原子，C1-6烷基或卤素原子; 条件是当R 3和R 4各自表示氢原子时，R 5不是氢原子。本发明还涉及包含所述衍生物或其盐作为活性成分的药物，其用于预防和/或治疗由GSK3β或GSK3beta以及cdk5 / p25例如阿尔茨海默病的异常活动引起的神经退行性疾病疾病。

8. 发明授权

US07214682B2 Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido{1,2-a}pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo{1,2-a}pyrimidin-5(1h)one derivatives 失效
公开(公告)号：US07214682B2
公开(公告)日：2007-05-08
申请号：US10490135
申请日：2002-09-19
申请人： Thierry Gallet , Patrick Lardenois , Alistair Lochead , Séverine Marguerie , Alain Nedelec , Mourad Saady , Franck Slowinski , Philippe Yaiche
发明人： Thierry Gallet , Patrick Lardenois , Alistair Lochead , Séverine Marguerie , Alain Nedelec , Mourad Saady , Franck Slowinski , Philippe Yaiche
IPC分类号： A01N43/90 , A61K31/519 , A01N43/62 , A61K31/55 , C07D471/00 , C07D487/00
CPC分类号： A01N43/90 , C07D213/50 , C07D213/60 , C07D487/04
摘要： The invention relates to a pyrimidone derivative represented by formula (I) or a salt thereof wherein X represents two hydrogen atoms, a sulfur atom, an oxygen atom or a C1-2 alkyl group and a hydrogen atom; Y represents a bond, an ethenylene group, an ethynylene group an oxygen atom, a sulfur atom, a sulfonyl group, a sulfoxide group, a carbonyl group, a hydroxyiminomethylene group, a dioxolan group, a nitrogen atom being optionally substituted; or a methylene group optionally substituted; or a methylene group optionally substituted; R1 represents a 2, 3 or 4-pyridine ring optionally substituted; R2 may represent a C1-6 alkyl group optionally; a C3-6 cycloalkyl group, a C1-4 alkythio group, a C1-4 alkoxy group, a C1-2 perhalogenated alkyl group, a C1-3 halogenated alkyl group, a phenylthio group, a benzyl group, a benzene ring, an indan ring, a 5,6,7,8-tetrahydronaphthalene ring, a naphthalene ring, a pyridine ring, a pyrrole ring, a thiophene ring, a furan ring or an imidazole ring; R3 and R4 represent, each independently, a hydrogen atom, a C1-6 alkyl group, a hydroxy group, a C1-4 alkoxy group or a halogen atom; R5 represents a hydrogen atom, a C1-6 alkyl group or a halogen atom; with the proviso that when R3 and R4 represent each a hydrogen atom then R5 is not a hydrogen atom. The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β or GSK3β, and cdk5/p25, such as Alzheimer disease

9. 发明授权

US07388005B2 Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo [1,2-a]pyrimidin-5(1H)one derivatives for neurodegenerative disorders 失效
标题翻译：取代的2-嘧啶基-6,7,8,9-四氢嘧啶并[1,2-a]嘧啶-4-酮和7-嘧啶基-2,3-二氢咪唑并[1,2-a]嘧啶-5（1H）神经变性疾病的衍生物
公开(公告)号：US07388005B2
公开(公告)日：2008-06-17
申请号：US10490136
申请日：2002-09-19
申请人： Thierry Gallet , Patrick Lardenois , Alistair Lochead , Séverine Marguerie , Alain Nedelec , Mourad Saady , Franck Slowinski , Philippe Yaiche
发明人： Thierry Gallet , Patrick Lardenois , Alistair Lochead , Séverine Marguerie , Alain Nedelec , Mourad Saady , Franck Slowinski , Philippe Yaiche
IPC分类号： A61K31/551 , A61K31/519 , C07D487/04 , A61P25/28
CPC分类号： A61K31/519 , A61K31/551 , C07D487/04
摘要： The invention relates to a pyrimidone derivative represented by formula (I) or a salt thereof wherein: X represents two hydrogen atoms, a sulphur atom, an oxygen atom or a C1-2 alkyl group and a hydrogen atom; y represents a bond, an ethenylene group, an ethynylene group, an oxygen atom, a sulphur atom, a sulfonyl group, a sulfoxide group, a carbonyl group, a nitrogen atom being optionally; or a methylene group optionally substituted; R1 represents a pyrimidine group optionally substituted; R2 may represent a C1-6 alkyl group optionally substituted by a C6,10 aryloxy or a C6,10 arylamino group; a C3-6 cycloalkyl group, a C1-4 alkylthio group, a C1-4 alkoxy group, a C1-2 perhalogenated alkyl group, a C1-3 halogenated alkyl group, a phenylthio group, a benzyl group, a benzene ring, an indan ring, a 5,6,7,8-tetrahydronaphthalene ring, a naphthalene ring, a pyridine ring, a pyrrole ring, a thiophene ring, a furan ring or an imidazole ring; R3 and R4 represents each independently a hydrogen atom, C1-6 alkyl group, a hydroxy group, a C1-4 alkoxy group or a halogen atom; R5 represents a hydrogen atom, a C1-6 alkyl group or a halogen atom. The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β3 or GSK3β3 and cdk5/p25, such as Alzheimer disease.
摘要翻译：本发明涉及由式（I）表示的嘧啶酮衍生物或其盐，其中：X表示两个氢原子，硫原子，氧原子或C 1-12烷基和氢原子; y表示键，亚乙烯基，亚乙炔基，氧原子，硫原子，磺酰基，亚砜基，羰基，任选的氮原子; 或任选取代的亚甲基; R1表示任选取代的嘧啶基团; R 2可以表示任选被C 6,10芳氧基或C 6,10芳基氨基取代的C 1-6烷基; C 3-6环烷基，C 1-4烷硫基，C 1-4烷氧基，C 1 -C 4烷氧基， 1-2个全卤代烷基，C 1-3卤代烷基，苯硫基，苄基，苯环，茚满环，5,6,7， 8-四氢萘环，萘环，吡啶环，吡咯环，噻吩环，呋喃环或咪唑环; R 3和R 4各自独立地表示氢原子，C 1-6烷基，羟基，C 1-4烷氧基或卤素原子; R5表示氢原子，C 1-6烷基或卤素原子。本发明还涉及包含所述衍生物或其盐作为活性成分的药物，其用于预防和/或治疗由GSK3β3或GSK3β3和cdk5 / p25的异常活性引起的神经变性疾病，例如阿尔茨海默病。

10. 发明授权

US08273758B2 Substituted tricyclic derivatives 有权
标题翻译：取代三环衍生物
公开(公告)号：US08273758B2
公开(公告)日：2012-09-25
申请号：US12968927
申请日：2010-12-15
申请人： Antonio Almario Garcia , Alistair Lochead , Mourad Saady , Philippe Yaiche
发明人： Antonio Almario Garcia , Alistair Lochead , Mourad Saady , Philippe Yaiche
IPC分类号： A01N43/54 , A61K31/505 , C07D239/00 , C07D487/00
CPC分类号： A01N43/54 , C07D487/04 , C07D519/00
摘要： Compounds of formula (I): wherein: Z, R1, R2, R3, n, and m are as defined in the disclosure. Also disclosed are methods of preparing the compounds of formula (I) and their use in therapeutics.
摘要翻译：式（I）化合物：其中：Z，R 1，R 2，R 3，n和m如本公开所定义。还公开了制备式（I）化合物及其在治疗中的用途的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式